JP2015534990A5 - - Google Patents

Download PDF

Info

Publication number
JP2015534990A5
JP2015534990A5 JP2015538124A JP2015538124A JP2015534990A5 JP 2015534990 A5 JP2015534990 A5 JP 2015534990A5 JP 2015538124 A JP2015538124 A JP 2015538124A JP 2015538124 A JP2015538124 A JP 2015538124A JP 2015534990 A5 JP2015534990 A5 JP 2015534990A5
Authority
JP
Japan
Prior art keywords
aryl
group
alkyl
amino
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015538124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534990A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/066041 external-priority patent/WO2014066304A1/en
Publication of JP2015534990A publication Critical patent/JP2015534990A/ja
Publication of JP2015534990A5 publication Critical patent/JP2015534990A5/ja
Pending legal-status Critical Current

Links

JP2015538124A 2012-10-22 2013-10-22 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法 Pending JP2015534990A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261716987P 2012-10-22 2012-10-22
US61/716,987 2012-10-22
US201261735458P 2012-12-10 2012-12-10
US61/735,458 2012-12-10
PCT/US2013/066041 WO2014066304A1 (en) 2012-10-22 2013-10-22 Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e

Publications (2)

Publication Number Publication Date
JP2015534990A JP2015534990A (ja) 2015-12-07
JP2015534990A5 true JP2015534990A5 (enExample) 2016-12-08

Family

ID=50545165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015538124A Pending JP2015534990A (ja) 2012-10-22 2013-10-22 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法

Country Status (7)

Country Link
US (1) US9409901B2 (enExample)
EP (1) EP2909203A4 (enExample)
JP (1) JP2015534990A (enExample)
AU (1) AU2013334860B2 (enExample)
CA (1) CA2888889A1 (enExample)
IL (1) IL238415B (enExample)
WO (1) WO2014066304A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017015456A (es) * 2015-06-01 2018-11-29 Bantam Pharmaceutical Llc Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.
CA3081983A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
MX2019006296A (es) 2016-11-30 2019-11-12 Bantam Pharmaceutical Llc Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas.
EP4026567A4 (en) * 2019-09-03 2024-04-24 Sovargen Co., Ltd. Composition for diagnosing or treating conditions associated with increased elf4e activity comprising elf4e inhibitor
US20240052004A1 (en) * 2019-10-04 2024-02-15 Yale University Targeting cap-dependent translation to reduce seizures in mtor disorders
IL296139A (en) * 2020-03-03 2022-11-01 Pic Therapeutics Inc Eif4e inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
MXPA06012130A (es) * 2004-04-20 2007-01-31 Transtech Pharma Inc Derivados de tiazol y pirimidina substituidos como moduladores del receptor de melanocortina.
US8257931B2 (en) * 2005-01-21 2012-09-04 President And Fellows Of Harvard College Regulation of protein synthesis
GB0614068D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
GB0614070D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
US8318735B2 (en) 2006-10-31 2012-11-27 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
CA2694218A1 (en) * 2007-07-31 2009-02-05 Schering Corporation Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
AU2011276539A1 (en) 2010-06-28 2013-02-07 President And Fellows Of Harvard College Compounds for the inhibition of cellular proliferation

Similar Documents

Publication Publication Date Title
JP2016528301A5 (enExample)
JP2015534990A5 (enExample)
EA025086B9 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
NZ708593A (en) Novel pyrazole derivative
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2014011946A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
EP4227304A3 (en) Thiadiazole analogs and their use for treating diseases associated with a deficiency of smn motor neurons
EP4275748A3 (en) Compositions and methods for treating cns disorders
NZ700374A (en) New therapeutic approaches for treating parkinson’s disease
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12014500239A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
JP2014513136A5 (enExample)
IN2014DN05869A (enExample)
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
IN2014DN08582A (enExample)